
Artivion (AORT) Stock Forecast & Price Target
Artivion (AORT) Analyst Ratings
Bulls say
Artivion is expected to see double-digit growth in the next fiscal year, thanks to their successful launch of the AMDS and strong performance in their aortic stent and surgical sealant businesses. However, their preservation services segment has underperformed, and there are potential risks in terms of delays in clinical trials. The company is actively pursuing international expansion and has a strong product pipeline for future growth and potential acquisitions.
Bears say
Artivion is facing a negative outlook due to slowing revenue growth, weak international expansion, and potential delays in clinical trials or new product approvals which could result in disappointing sales and weaker operating margins. The company ended Q4/25 with $65M in cash and $215M in debt, and its recent valuation is based on a 4.6x EV/Sales multiple, a 15% premium to the mean 2026E mid-cap Med-Tech comp group, applied to estimated 2027 revenue of $555M.
This aggregate rating is based on analysts' research of Artivion and is not a guaranteed prediction by Public.com or investment advice.
Artivion (AORT) Analyst Forecast & Price Prediction
Start investing in Artivion (AORT)
Order type
Buy in
Order amount
Est. shares
0 shares